Navigation Links
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Date:12/17/2007

Roche in collaboration with Genentech commit to large phase III adjuvant

clinical programme set to unlock Avastin's potential in early breast

SAN ANTONIO, Dec. 17 /PRNewswire/ -- According to new phase II study data, Avastin (bevacizumab) can proceed to be tested after breast cancer surgery in combination with anthracycline containing regimens. These findings pave the way for Avastin's use as a curative treatment for women with this devastating disease. Data presented today at the San Antonio Breast Cancer Symposium (SABCS) from the E2104 study showed that standard anthracycline-based chemotherapy (doxorubicin) can be added to Avastin after surgical removal of the breast tumour, without a concerning increase in the incidence of cardiac adverse events typically associated with this form of chemotherapy.

These data support the commencement of phase III adjuvant breast cancer clinical programme which will include over 10,000 patients with early stage breast cancer. Avastin already offers women with late-stage (metastatic) breast cancer the chance to live twice as long without their disease progressing (1).

"The unique way Avastin works also lends itself for use in women with earlier stages of breast cancer" said Dr Kathy Miller of Indiana University School of Medicine, USA and principal investigator of the E2104 study. "We now know that Avastin use in combination with anthracyclines does not result in concerning rates of cardiac dysfunction in the adjuvant setting and armed with this evidence Avastin's impact can be fully validated in a large worldwide phase III clinical trial programme."

Data from the E2104 study have shown that cardiac dysfunction is not a major concern with the treatment combination of Avastin and doxorubicin. As presented in SABCS, two patients with symptomatic congestive heart failure were reported in each of the 2 Avastin-containing treatment arms which included more than 100 patie
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
2. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... antibodies for the treatment of autoimmune diseases, asthma and ... Yujiro S. Hata to its board of ... business and corporate development is a tremendous asset to ... and chief executive officer of Xencor. "Xencor faces a ...
(Date:7/30/2015)... 30, 2015 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the ... have him on Edwards, board as we pursue our focused ... and CEO.  "Bob has provided a valuable perspective to our ...
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... Northern Ireland, Dec. 20, 2010 HeartSine Technologies ... the 14th annual Aisling Awards ceremony, November 25th, in ... who has made significant contributions to Belfast and surrounding ... the Belfast Media Group in 1997 to ...
... Calif., Dec. 20, 2010 Huntsman Gay Global Capital, ... the completion of a recapitalization of Sunquest Information Systems® ... recapitalization, led by Huntsman Gay, was done in partnership ... since 2007 and is retaining a significant stake in ...
Cached Medicine Technology:HeartSine Technologies Wins 2010 Aisling Award for Outstanding Achievement in Business 2Huntsman Gay-Led Consortium Completes Recapitalization of Sunquest Information Systems 2Huntsman Gay-Led Consortium Completes Recapitalization of Sunquest Information Systems 3
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional Products International, a company ... wellness products, announced the addition of Vincent Aquilino to its Board of Directors. ... and the prevention and rehabilitation of injuries, has spent the last 17-plus years ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... base, with the recent implementation of Microsoft Dynamics GP for a senior living ... Intellitec is now supporting senior living communities in 16 states. This further expansion ...
(Date:7/31/2015)... Orange, NJ (PRWEB) , ... July 31, 2015 ... ... obstructive sleep apnea (OSA) and the growing number of individuals who remain undiagnosed, ... of Americans continue to shy away from traditional CPAP therapy due to its ...
(Date:7/30/2015)... ... 31, 2015 , ... Reduce Human Error on the Drug ... and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice ... and device firms reduce manufacturing errors by 50 percent or more, will conduct ...
(Date:7/30/2015)... Dobbs Ferry, New York (PRWEB) , ... July 31, 2015 , ... ... President Barack Obama’s call to action by asking community members to contribute to the ... focused on, “Helping more of our young people stay on track. Providing the support ...
Breaking Medicine News(10 mins):Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3
... Comparative trials and observational studies previously conducted in ... These studies were performed before intracoronary stents and ... ,Therefore, Dr. Hanoch Hod, of Chaim Sheba ... followed 130 consecutive patients aged 70 or older ...
... vasectomy, contraception is typically left up to the woman. ... in a woman's contraceptive repertoire. Until now, men have ... searching for new options. Now, they may have one.// ... 12 percent. Vasectomies are considered permanent. Dr. Wang, of ...
... of choice for some doctors who think it's time to ... French physician invented it in the early 1800s. "The stethoscope ... allow you to distinguish between a heart that is beating ... ,"Sometimes the heart muscle is very weakened, but unless that ...
... spreads fast, and when it does, it can kill within months. ... tracks. ,Faith was more than a mere crutch for Rev. Jerry ... afraid of dying. My faith sustained me in that, but I ... highly curable if it's caught early, but it does not respond ...
... be found in water which has flowed through arsenic-rich ... drinking arsenic-rich water over long periods in countries world-wide. ... the earth's crust. ,Arsenic is introduced into water through ... groundwater //in some areas are elevated as a result ...
... affects women of child-bearing age, occurs when the the ... rendering them unable to produce eggs. PCOS symptoms include ... have said women// without these symptoms still can have ... though women's health experts caution that not every woman ...
Cached Medicine News:Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Arsenic in drinking water 2Health News:Arsenic in drinking water 3Health News:Arsenic in drinking water 4Health News:Arsenic in drinking water 5Health News:Arsenic in drinking water 6Health News:Arsenic in drinking water 7Health News:Arsenic in drinking water 8Health News:Polycystic Ovarian Syndrome(PCOS) linked to Diabetes 2
For use in cleaning soft contact lenses. Sensitive Eyes daily cleaner loosens and removes accumulations of film, deposits, and debris from soft contact lenses. Use with heat, chemical, and hydrogen p...
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
Renu rewetting drops soothe your eyes and moisturize soft contact lenses to minimize dryness....
Softwear Saline with unique comfort rinsing formula....
Medicine Products: